Leukocyte telomere length is associated with complications of Type 2 diabetes mellitus

被引:84
|
作者
Testa, R.
Olivieri, F. [1 ,3 ]
Sirolla, C. [4 ]
Spazzafumo, L. [4 ]
Rippo, M. R. [1 ]
Marra, M. [2 ]
Bonfigli, A. R. [2 ]
Ceriello, A. [5 ,6 ]
Antonicelli, R. [7 ]
Franceschi, C. [8 ]
Castellucci, C. [1 ]
Testa, I. [2 ]
Procopio, A. D. [1 ,3 ]
机构
[1] Univ Politecn Marche, Dept Mol Pathol & Innovat Therapies, I-60100 Ancona, Italy
[2] INRCA Ancona, Metab & Nutr Res Ctr Diabet, Ancona, Italy
[3] INRCA Ancona, Ctr Clin Pathol & Innovat Therapy, Ancona, Italy
[4] INRCA Ancona, Ctr Stat, Ancona, Italy
[5] Insi Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain
[6] Ctr Invest Biomed Red Diabet & Enfermedades Metab, Barcelona, Spain
[7] INRCA Ancona, Cardiol Unit, Ancona, Italy
[8] Univ Bologna, Dept Expt Pathol, I-40126 Bologna, Italy
关键词
diabetes complications; telomeres; CORONARY-ARTERY-DISEASE; OXIDATIVE STRESS; SENESCENCE; CELLS; RISK;
D O I
10.1111/j.1464-5491.2011.03370.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective The key goal of diabetes management is to prevent complications. While the patho-physiological mechanisms responsible for diabetes complications have been extensively studied, at present it is impossible to predict which patient with diabetes could develop complications. In recent years, the role of leukocyte telomere length in the pathogenesis of cardiovascular disease and Type 2 diabetes has been investigated. However, studies aiming to investigate the role of telomeres in the development and progression of Type 2 diabetes, as well as diabetic complications, are still lacking. As a consequence, this study aimed to verify whether leukocyte telomere length is associated with the presence and the number of diabetic complications in a sample of patients with Type 2 diabetes. Methods This is a cross-sectional study. Nine hundred and one subjects were enrolled, including 501 patients with Type 2 diabetes, of whom 284 had at least one complication and 217 were without complications, and 400 control subjects. Leukocyte telomere length was measured by quantitative real-time PCR. Results Patients with diabetes complications had significantly shorter leukocyte telomere length than both patients without diabetes complications and healthy control subjects. Moreover, among patients with diabetes complications, leukocyte telomere length became significantly and gradually shorter with the increasing number of diabetes complications. The magnitude of the effect of the decrease of the abundance of telomeric template vs. a single-copy gene length (T/S ratio) on complications is described by the estimated odds ratio OR = 5.44 (95% CI 3.52-8.42). Conclusions The results of the study support the hypothesis that telomere attrition may be a marker associated with the presence and the number of diabetic complications.
引用
收藏
页码:1388 / 1394
页数:7
相关论文
共 50 条
  • [1] Association of leukocyte telomere length with metabolic syndrome in type 2 diabetes mellitus
    Peng, Xuemin
    Huang, Jiaojiao
    Xia, Sanshan
    Yang, Yan
    Dong, Kun
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2021, 26 (01):
  • [2] The Association between Antidiabetic Agents and Leukocyte Telomere Length in the Novel Classification of Type 2 Diabetes Mellitus
    Huang, Jiaojiao
    Peng, Xuemin
    Dong, Kun
    Tao, Jing
    Yang, Yan
    GERONTOLOGY, 2021, 67 (01) : 60 - 68
  • [3] Mean leukocyte telomere length shortening and type 2 diabetes mellitus: a case-control study
    Zee, Robert Y. L.
    Castonguay, Amy J.
    Barton, Nathaniel S.
    Germer, Soren
    Martin, Mitchell
    TRANSLATIONAL RESEARCH, 2010, 155 (04) : 166 - 169
  • [4] Leukocyte Telomere Length as a Marker of Chronic Complications in Type 2 Diabetes Patients: A Risk Assessment Study
    Sawicki, Krzysztof
    Matysiak-Kucharek, Magdalena
    Gorczyca-Siudak, Daria
    Kruszewski, Marcin
    Kurzepa, Jacek
    Kapka-Skrzypczak, Lucyna
    Dziemidok, Piotr
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (01)
  • [5] Short telomere length is associated with arterial aging in patients with type 2 diabetes mellitus
    Dudinskaya, E. N.
    Tkacheva, O. N.
    Shestakova, M. V.
    Brailova, N. V.
    Strazhesko, I. D.
    Akasheva, D. U.
    Isaykina, O. Y.
    Sharashkina, N. V.
    Kashtanova, D. A.
    Boytsov, S. A.
    ENDOCRINE CONNECTIONS, 2015, 4 (03): : 136 - 143
  • [6] Association of type 2 diabetes with leukocyte telomere length and cardiovascular aging
    Plokhova, E. V.
    Tkacheva, O. N.
    Akasheva, D. U.
    Strazhesko, I. D.
    Kruglikova, A. S.
    Dudinskaya, E. N.
    Boytsov, S. A.
    EUROPEAN HEART JOURNAL, 2013, 34 : 452 - 452
  • [7] Leukocyte telomere length and mortality risk in patients with type 2 diabetes
    Bonfigli, Anna Rita
    Spazzafumo, Liana
    Prattichizzo, Francesco
    Bonafe, Massimiliano
    Mensa, Emanuela
    Micolucci, Luigina
    Giuliani, Angelica
    Fabbietti, Paolo
    Testa, Roberto
    Boemi, Massimo
    Lattanzio, Fabrizia
    Olivieri, Fabiola
    ONCOTARGET, 2016, 7 (32) : 50835 - 50844
  • [8] Associations of TERC Single Nucleotide Polymorphisms with Human Leukocyte Telomere Length and the Risk of Type 2 Diabetes Mellitus
    Al Khaldi, Rasha
    Mojiminiyi, Olusegun
    AlMulla, Fahd
    Abdella, Nabila
    PLOS ONE, 2015, 10 (12):
  • [9] The shortening of leukocyte telomere length relates to DNA hypermethylation of LINE-1 in type 2 diabetes mellitus
    Wu, Yue
    Cui, Wei
    Zhang, Donghong
    Wu, Wei
    Yang, Zhuo
    ONCOTARGET, 2017, 8 (43) : 73964 - 73973
  • [10] Shortened Relative Leukocyte Telomere Length Is Associated With Prevalent and Incident Cardiovascular Complications in Type 2 Diabetes: Analysis From the Hong Kong Diabetes Register
    Cheng, Feifei
    Luk, Andrea O.
    Tam, Claudia H. T.
    Fan, Baoqi
    Wu, Hongjiang
    Yang, Aimin
    Lau, Eric S. H.
    Ng, Alex C. W.
    Lim, Cadmon K. P.
    Lee, Heung Man
    Chow, Elaine
    Kong, Alice P.
    Keech, Anthony C.
    Joglekar, Mugdha V.
    So, Wing Yee
    Jenkins, Alicia J.
    Chan, Juliana C. N.
    Hardikar, Anandwardhan A.
    Ma, Ronald C. W.
    DIABETES CARE, 2020, 43 (09) : 2257 - 2265